Render Target: SSR
Render Timestamp: 2024-12-19T21:28:54.264Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:58:55.747
Product last modified at: 2024-12-17T18:59:22.380Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PAPSS1 (E6U5C) Rabbit mAb #68533

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 70
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    PAPSS1 (E6U5C) Rabbit mAb recognizes endogenous levels of total PAPSS1 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PAPSS1 protein.

    Background

    PAPS Synthase 1 and 2 (PAPSS1, PAPSS2) are bifunctional enzymes with both ATP sulfurylase and APS kinase activity. They mediate two reactions to generate 3'-phosphoadenosine-5'-phosphosulfate (PAPS), a critical intermediate in the sulfate activation pathway. PAPS is the sulfate donor co-substrate for all sulfotransferase (SULT) enzymes and is required to catalyze the sulfate conjugation of many endogenous and exogenous compounds (1,2). For example, PAPSS1 and PAPSS2 are responsible for catalyzing the sulfation of steroid hormones, which increases their water solubility and reduces their biological activity, suggesting modulation of PAPS synthases as a possible avenue for treatment of hormone-dependent cancers (3). Inhibition of PAPSS1 was also shown to increase the sensitivity of some cancer cell lines to DNA-damage agents both in vitro and in vivo (4,5), suggesting further potential utility for PAPS synthase inhibitors in cancer therapy.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.